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Hydroxychloroquine, an antimalarial, is being used worldwide for prophylaxis and treatment of Corona virus disease-19 
(COVID-19). Though the drug is commonly used in many chronic inflammatory diseases for protracted periods, its safety in 
the new indication is still under scrutiny. Therefore, this institute based study sought to assess the acute adverse effects of 
hydroxychloroquine among in-house health care professionals who were taking the drug for COVID-19 prophylaxis. A 
questionnaire seeking information on the use of the drug was prepared and disseminated electronically to the target 
population. The responses were also received electronically and analysed. The participants (n=54) had taken prophylaxis for 
1-7 weeks. The most common adverse effects in the cohort were nausea (02) and skin rash (02). The total number of adverse
effects reported by the participants was 08. One incidence each of gastric upset (01), dizziness (01), pain abdomen (01), and
chest tightness (01) was reported. None of the adverse effects were serious. Our study indicates that the prophylactic weekly
single dose of hydroxychloroquine is not associated with any serious adverse effects within 1-7 weeks of initiation.
Elucidation of the long term and chronic adverse effects, if any, requires further studies.
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Coronaviruses are a large family of viruses that cause 
illness in humans and animals. In humans, several 
corona viruses cause respiratory infections which can 
present as mild to more severe diseases, such as 
Middle East Respiratory Syndrome (MERS) and 
Severe Acute Respiratory Syndrome (SARS)
1,2
.  
In the month of December 2019, Wuhan, China 
first reported that patients were suffering from an 
infection characterized with atypical pneumonia, 
fever, dry cough, and progressive dyspnoea with 





 February 2020, 
the virus and the disease were renamed as severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and COVID-19 by the International 
Committee on Taxonomy of Viruses (ICTV) and 
World Health Organization (WHO), respectively
4,5
. 
Within around three months, the viral infection spread 
rapidly to most parts of the world, prompting the 
WHO to declare COVID-19 as pandemic on 11
th
 
March 2020. In absence of any effective drug against 
the virus, the infection rate and mortality are high and 
as per the information with the WHO-COVID-19 
dashboard, as of 31
st 
July 2020, there have been 17, 
106, 007 confirmed cases of COVID-19, including 
668, 910 deaths worldwide
4
. Any hope of controlling 
the pandemic with a newly developed drug is far from 
practical because drug development is a time-taking 
and costly process. Testing drugs from the existing 
―armamentarium‖ of approved drugs (but for other 
indication) against a disease, popularly known as drug 
repurposing, is a viable alternative in the current 
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ivermectin (IVM), and azithromycin (AZT) have 
potential efficacy against the virus and are already in 
clinical trials worldwide
2
. HCQ and IVM are known 
to act by creating an acidic environment and 
inhibiting the importin (IMPα/β1) mediated viral 
import, respectively. Like HCQ, AZT (a weak base) is 
observed to have an acidotropic action. The anti-viral 
action of these drugs including chloroquine (CQ) and 
its congener HCQ were noted in vitro which 
warranted further exploration in the infection
6
. While 
CQ is better known for the treatment of malaria, HCQ 
is commonly used for the treatment of chronic 
diseases like rheumatoid arthritis and Systemic lupus 
erythematosus (SLE)
7
. HCQ is preferred in these 
chronic conditions because of lesser toxicity and  
long-term side effects compared to CQ. HCQ is 
synthesised by the addition of a hydroxyl group at the 
end of the side chain of CQ (Fig. 1). This minor 
structural modification alters the pharmacokinetics of 
the molecule, such that the molecule has decreased 
tissue affinity and lesser accumulation in tissues, and 
therefore, lesser chances of retinal damage and 
corneal opacity when prescribed for longer periods. In 
addition to the better safety profile of HCQ, the 
efficacy of antiviral activity of the molecule has also 





 March 2020, the Indian Council of Medical 
Research (ICMR) recommended hydroxychloroquine 
as prophylaxis to asymptomatic healthcare workers 
involved in the care of suspected or confirmed cases 
of COVID-19 and asymptomatic household contacts 
of laboratory-confirmed cases with the dose of  
400 mg twice daily in day one, then 400 mg once 
weekly for 7 weeks for healthcare providers and  
3 weeks for asymptomatic household contacts. The 
prophylactic therapy excludes the children below  
15 years of age
8
. Thereafter, on the 22
nd
 May 2020 
ICMR recommended to continuing weekly 
prophylactic therapy for health care providers 
(involved in COVID-19 related activities) with strict 




Aims and Objectives 
In this study, we sought to study the safety and 
tolerability of the initiation of Hydroxychloroquine in 
the prophylaxis of COVID-19 in a cohort of health 
care professionals.  
 
Subjects and Methods 
This study is limited to a tertiary care centre in 
eastern India directly involved in the management of 
COVID-19 patients. A 100 bedded covid dedicated 
hospital, an RT-PCR testing laboratory for COVID-19, 
a separate fever clinic, and a quarantine unit with 
health care personnel, managed and run by health care 
providers of the institution. According to the advisory 
recommendation of ICMR, prophylactic therapy of 
HCQ is being voluntarily taken by many health care 
professionals. This web- based study was conducted 
to collect data on the potential adverse effects of 
prophylactic use of HCQ for COVID-19 by health 
care professionals of the institution.  
 
Subject Selection Criteria 
Healthcare providers who were taking HCQ as 
prophylaxis for COVID-19 were included in this 
study. Those persons taking HCQ due to autoimmune 
diseases like rheumatoid arthritis or Systemic Lupus 
Erythematous (SLE) or any other conditions were 
excluded from the study.  
 
Study Tool  
A questionnaire was prepared using a set of 
questions to elicit information on demographic, 
clinical characteristics, drug-taking behaviour, and 
adverse effects of HCQ in the respondents. The 
questionnaire was transcribed in Google Form (a web- 
 
 
Fig. 1 — Structure of chloroquine and hydroxychloroquine. 
Chemically, chloroquine is 4-N-(7-chloroquinolin-4-yl)-1-N, 
1-N-diethylpentane-1,4-diamine. Substitution of the H atom at the 
end of diethyl-pentane side chain with hydroxyl moiety yields 
hydroxychloroquine 




based survey tool) and was disseminated electronically 
using freely available mobile phone applications. 
Health care providers were requested to fill up and 
submit the form as per convenience. No force or 
coercion was employed during the study and the 
employees were free to take decision to participate in 
the study. The study and the questionnaire were 
approved by the Institutional Ethics Committee (IEC) 
(Ref. No. F-24/PR/COMJNMH/IEC/20/318) 
 
Statistical Analysis  
Data were processed and analysed at the 
Department of Pharmacology, College of Medicine 
and JNM Hospital, WBUHS, Kalyani. Analyses were 
done only after the last participant submitted the 
response on 31
st
 May 2020. Frequency in groups and 
the number of events were reported. Percentage 
calculation was used wherever applicable.  
 
Results and Analysis 
Fifty-four (32 males and 22 females) health care 
personnel of the institution filled-up and submitted the 
questionnaire, during April-May 2020. The data in all 
the submissions were complete and eligible for 
analysis. The number of participants in the age (in 
years) range <30, 30-39, 40-49, 50-59, and >60 was 3, 
26, 18, 6 and 1, respectively. While the majority of 
the participants were medical doctors (post-
graduates/graduates=46/4), 4 non-doctor (post-
graduates/graduates=2/2) participants were present in 
the final sample size of 54. Most of the participants 
were on prophylactic HCQ even before the 
commencement of the study. The number of 
participants who had completed 1, 2, 3, 4, 5, 6, and 7 
weeks of therapy at the time of submission of the 
form was 2, 2, 7, 21, 11, 6, and 5, respectively. 
Although ICMR advisory is to take HCQ with a meal, 
the majority of participants (43) took HCQ after meal. 
Only 6 participants (11. 11%) accurately followed the 
guideline of consuming the medicine during the meal. 
A few participants (5) even consumed the drug before 
meal. The incidental and pre-existing presence of 
hypertension, diabetes, asthma, peptic ulcer/gastritis 
and ankylosing spondylosis was observed in 8, 2, 6, 1, 
and 1 participants, respectively. The remaining 36 
subjects were free from any co-morbid condition. The 
total number of adverse effects reported by the 
participants following prophylactic HCQ was 08. Two 
participants experienced nausea which was reportedly 
relieved by oral self-administration of the anti-emetic 
ondansetron in the recommended dose. The adverse 
effect in both the participants had a temporal 
association with untimely intake of the drug with 
respect to meals- one had taken before a meal and the 
other had taken the medicine after light breakfast. A 
skin rash was also reported by 2 persons. Chest 
tightness was seen in one case, which however, 
recovered after 24 h without any medication. This 
chest tightness was experienced on repeat dose and 
the person stopped the use of hydroxychloroquine 
after 2
nd
 week. One incidence each of gastric upset 
(01), dizziness (01), and pain abdomen (01) was also 
reported. All the adverse effects were observed in the 
healthy participants and those with pre-existing 
ailments did not report any adverse event. No relation 
to the age of the participants was seen.  
 
Discussion  
Though the molecular action of hydroxychloroquine 
in COVID-19 is not known, several mechanisms have 
been postulated. The inhibitory action of the drug starts 
even before the virus could gain entry inside the cells. 
The virus interacts with angiotensin- converting enzyme 
2 (ACE2) on the host cell surface for internalisation. 
ACE2 is transmembrane glycoproteins with terminal 
sialic acid residues which act as the precise sites of the 
virus-host cell surface interaction. Hydroxychloroquine 
inhibits the cell membrane enzyme quinone reductase 2 
in the sialic acid biosynthetic pathway (Vide No. 1 in 
Fig. 2). The drug, therefore, causes failure of 
glycosylation of ACE2, leading to diminished virus-host 
receptor interaction. The entry of the virus into the host 
cell for propagation is curtailed and the chances of 
infection and progression of infection are reduced
10,11
. 
The inhibitory action of the drug against the virus 
continues inside the cell. Once inside the cell, the viral 
envelope fuses with the endosomal membrane and its 
nucleic acid is released into the cytoplasm (Vide No. 2 
in Fig. 2). This step is the trigger for viral replication and 
is heavily dependent on the acidic pH of the endosomal 
content. Chloroquine or its hydroxylated derivative 
accumulates inside and alkalinise the endosomal milieu 
and impedes the release of the viral genome
12
. After the 
replication phase, there is a post-translational 
modification (PTM) of the viral proteins in the acidic 
milieu of the endoplasmic reticulum (ER) and trans-
Golgi apparatus (TGA) (Vide No. 3 in Fig. 2). Finally, 
the assembly of replicated nucleic acid and translated 
viral proteins occurs, leading to the shedding of a huge 
number of viral progeny (Fig. 2). The drug, similar to its 
action in the endosomes, elevates the pH in ER and 
TGA and interferes with the step of PTM of the viral 






. The actions of the drug constitute a ―triune 
trouble‖ for the virus whereby the virus is 
chronologically inhibited at the three stages of the viral 
life cycle-entry, replication, and post-translational 
modification. 
Immuno-modulatory actions of the drug against the 
virus have been identified at three cellular sites- 
lysosomes, endosomes and the cytoplasm. In the two 
organelles,the drug shifts the pH from acidic to basic. 
Such alterations in the lysosomes of the antigen- 
presenting cells (B-cells, Dendritic cells), prevent the 
processing and presentation of antigens to the T-cells, 
impeding their activation. The production of 
inflammatory cytokines (IL-1, IL-6, TNF- etc.) by both 
the T and B cells are reduced (Vide No. 1 in Fig. 3). 
Similarly, altered pH in the endosomes interferes with 
binding between toll-like receptors (TLR7 and TLR9), 
and their RNA/DNA ligands and the inflammatory TLR 
signalling is suppressed
11
 (Vide No. 2 in Fig. 3).The anti-
inflammatory action of the drug in the cytoplasm is by 
the prevention of the cytosolic DNA-cyclic GMP/AMP 
synthase (cGAS) interaction. The interaction is known to 
increase inflammation by the Stimulation of Interferon 
Genes (the STING pathway) (Vide No. 3 in Fig. 3). So, 
the action mediated by the drug at the three sites- 
endosomes, lysosomes, and cytoplasm lead to precise 
anti-inflammatory action. The suppression of cytokine 
production can be life-saving because it is believed that 
the potentially fatal cytokine storm syndrome occurs due 
to the prodigious release of the immune mediators
14
.  
The in vitro anti-viral inhibitory actions of 
hydroxychloroquine together with the elicitation of its 
molecular mechanism of action has prompted many 
agencies to recommend its use for both treatment and 
prophylaxis. Being in use for chronic inflammatory 
conditions, the assumed safety of the drug and easy 
availability has lead to widespread use in the ongoing 
pandemic. Within a short period of time, conflicting 
reports on safety and efficacy have flooded the 
existing database of evidence, leaving much of the 
fraternity divided on its future use. At this juncture, it 
becomes imperative to investigate the role of the drug 
further. While the gold standard of efficacy analysis is 
a randomized controlled trial, which is being actively 
conducted globally, the issue of safety and tolerability 
can be addressed with the meticulously designed 
observational study. In the pandemic situation, where 
social distancing is the necessity rather than the norm, 
we conducted the entire study over the web. Though 
―armed‖ with a humble sample size of 54 ―front line 
warriors‖, the results are nevertheless optimistic as far 
as safety is concerned. In our study, hydroxychloroquine 
induced few adverse effects (8 episodes in 54 
subjects); all were mild in nature. No serious adverse 
effect was seen throughout this period. Out of 54 
persons, 2 persons had the experience of nausea, 
relieved by a single dose of oral ondansetron of 4 mg. 
Out of these 2 participants, one person took 
hydroxychloroquine before a meal and another person 
received after light breakfast. ICMR advised to take 
hydroxychloroquine during the meal to avoid this type 
of adverse effect. Skin rash was also noted in 2 
persons. One adverse effect of chest tightness was 
reported. The tightness disappeared after 24 h without 
any medication. The drug was discontinued after a 





Fig. 2 — Anti-viral activity of hydroxychloroquine (HCQ) against SARS-CoV-2 
 




The ECG was within the normal limits on both 
occasions. Other adverse effects were pain abdomen 
(single episode) and dizziness (disappeared within 12 h).  
Few studies on the adverse effects of HCQ in 
COVID-19 are available in literature. A countrywide 
web-based study found adverse events in 37. 9% of 
subjects in a sample size of 166
15
. The most common 
adverse event was observed from the gastrointestinal 
system (30. 7%)
15
. In comparison, we reported an 
adverse event in 14. 55% of the subjects with 
gastrointestinal adverse effect being observed in 50% 
(4 out of 8) of all events. Although QT prolongation 
and ventricular arrhythmia was noticed in few 
published case reports, no such adverse effects was 
seen in our study
14,16
. Interestingly, none of the 
participants in this study showed any symptoms of 
warranting testing for COVID-19 till 31
st
 July 2020.  
 
Limitations of the study 
The limitations of this study includes short duration 
of the study, the small sample size in a single centre, 
no follow up with the subjects and without any follow 
up investigations.  
 
Conclusion 
Our study indicates that the prophylactic weekly 
single dose of hydroxychloroquine is not associated 
with any serious adverse effects within 1-7 weeks of 
initiation of therapy. Elucidation of the long term, 
chronic adverse effects, and immunomodulatory 
actions, if any, requires further studies.  
 
Acknowledgement 
The authors are grateful to the staff and faculty 
members who participated in the study and sincerely 
acknowledge their contribution for the cause of 
humanity in the current pandemic situation. 
 
Conflict of interest 
All authors declare no conflict of interest.  
 
References  
1 Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, 
Zhang Z, Guan W, Ling Z, Jiang R, Hu T, Ding Y, Lin L, 
Gan Q, Luo L 3, Tang X & Liu J, Imaging and clinical 
features of patients with 2019 novel coronavirus SARS-CoV-2. 
Eur J Nucl Med Mol Imaging, 47 (2020) 1275.  
2 Das SK, The pathophysiology, diagnosis and treatment of 
corona virus disease 2019 (COVID-19). Indian J Clin 
Biochem, published online ahead of print (2020) 01 
3 Pandit K, Gupta S & Sharma AG, Clinico-Pathogenesis of 
COVID-19 in children. Indian J Biochem Biophys, 57 (2020) 
264.  
4 https://www. who. int/emergencies/diseases/novel-coronavirus-
2019/technical-guidance/naming-the-coronavirus-disease-
(COVID-2019)-and-the-virus-that-causes-it. (accessed on 31 
July 2020). 
5 Nina PB & Dash AP, Hydroxychloroquine as prophylaxis  
or treatment for COVID-19: what does the evidence say? 
Indian J Public Health, 64 (2020) S 125.  
6 Choudhary R & Sharma AK, Potential use of 
hydroxychloroquine, ivermectin and azithromycin drugs in 
fighting COVID-19: trends, scope and relevance. New 
 
 
Fig. 3 — Immunomodulatory action of HCQ in antigen presenting cells in SARS-CoV-2 viral infection 
 




Microbes New Infect, 35 (2020) 100684.  
7 Dörner T, Therapy: hydroxychloroquine in SLE: old drug, 
new perspectives. Nat Rev Rheumatol, 6 (2010) 10.  
8 Recommendation for empiric use of hydroxyl-chloroquine 
for prophylaxis of SARS-CoV-2 infection, published  
by ICMR on dated 22. 03. 2020 on https://www.icmr.gov.in/. 
9 A Revised advisory on the use of Hydroxychloroquine 
(HCQ) as prophylaxis for COVID-19 infection (in 
supersession of previous advisory dated 23rd March, 2020) 
guideline by ICMR, published by ICMR on dated 22. 03. 
2020 on https://www.icmr.gov.in/. 
10 Devaux CA, Rolain JM, Colson P & Raoult D, New insights 
on the antiviral effects of chloroquine against coronavirus: 
what to expect for COVID-19? Int J Antimicrob Agents, 55 
(2020) 105938.  
11 Roldan EQ, Biasiotto G, Magro P & Zanella I, The possible 
mechanisms of action of 4-aminoquinolines (chloroquine/ 
hydroxychloroquine) against Sars-Cov-2 infection (COVID-
19): A role for iron homeostasis? Pharmacol Res, 158 (2020) 
104904.  
12 Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, 
Shi Y & Sun E, Is hydroxychloroquine beneficial for 
COVID-19 patients? Cell Death Dis, 11 (2020) 512.  
13 Das S, Bhowmick S, Tiwari S & Sen S, An updated 
systematic review of the therapeutic role of hydroxychloroquine 
in Coronavirus Disease-19 (COVID-19). Clin Drug Investig, 
40 (2020)591.  
14 Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, 
Gelfand JA, Callahan MV, Kim AY, Reeves PM & 
Poznansky MC, Rethinking the role of hydroxychloroquine 
in the treatment of COVID-19. FASEB J, 34 (2020) 6027.  
15 Nagaraja BS, Ramesh KN, Dhar D, Mondal MS,  
Dey T, Saha S, Khan MA, Rutul SD, Pratik K, Manjula J, 
Sangeeth TA & Singh V, HyPE study: hydroxychloroquine 
prophylaxis-related adverse events analysis among healthcare 
workers during COVID-19 pandemic: a rising public health 
concern. J Public Health (Oxford), 42 (2020) 493.  
16 Abdelmaseih R, Abdelmasih R, Hasan M, Tadepalli S  
& Patel J, Serious adverse events associated with 
hydroxychloroquine amidst COVID-19 pandemic: case 
series and literature review. Cureus, 12 (2020) e8415.  
 
